Amgen Rallies After Q4; CVS Cuts Prolia Access Now

Amgen Rallies After Q4; CVS Cuts Prolia Access Now

Introduction

Amgen (AMGN) delivered a powerful earnings beat and upbeat guidance that pushed the Dow component to new highs this week, but the rally collided with a concrete commercial threat when CVS announced formulary changes favoring biosimilars for certain osteoporosis therapies. The juxtaposition of strong operational momentum and immediate pricing pressure makes AMGN a stock underscored by both opportunity and clear downside catalysts.

Strong Q4 Results and Immediate Market Reaction

What the earnings showed

Amgen reported robust fourth-quarter results highlighted by double-digit gains in GAAP EPS and broad product strength. Total Q4 revenue rose into the high single-digits year-over-year, with multiple products delivering record annual sales and several exceeding the $1 billion annual-sales mark. Management backed its 2026 outlook, reinforcing the view that Amgen’s diversified biologics portfolio is producing durable cash flow.

Price action: surge then consolidation

The earnings beat triggered an initial rally—shares climbed into fresh 52-week highs on heavy volume—but the move proved short-lived as some investors rotated to take gains. AMGN jumped sharply in the first sessions after results, then retraced about 3% within days and finished the week modestly lower versus the immediate post-earnings peak. That pattern is characteristic of a stock that cleared technical buy zones but became extended, prompting profit-taking and consolidation around the 50-day moving average.

CVS Formulary Change: A Concrete Biosimilar Headwind

What changed and why it matters

CVS announced it will remove Amgen’s Prolia from select formularies effective April 1 and substitute lower-cost biosimilars. Unlike vague competition talk, this is a specific commercial decision that materially affects prescription flow through a major pharmacy benefit manager. Prolia is a high-margin biologic that contributed meaningfully to Amgen’s revenue stream; shifting volume to biosimilars can reduce per-prescription revenue by a substantial percentage and compress overall revenue growth for relevant franchises.

Near-term revenue implications

While Amgen’s broad portfolio cushions the company against a single-product shock, the CVS move directly targets a legacy biologic with over a billion dollars in annual sales. Payer-driven formulary shifts tend to accelerate biosimilar uptake, so the change increases the probability of meaningful revenue erosion for Prolia in 2026 unless Amgen negotiates new contracting terms or offsets losses with gains elsewhere in the portfolio.

Analyst Views and Technical Picture

Upgrades and target revisions

Following the earnings release, several analysts raised price targets and reiterated positive stances, pointing to Amgen’s cash generation and pipeline breadth. Price targets vary—some in the high-$300s to low-$400s—reflecting confidence in core growth but different assumptions about biosimilar penetration and valuation. The divergent targets emphasize that upside remains, but valuation and execution risks are being heavily debated by the sell-side.

Technical indicators

Technically, AMGN moved into leadership territory after clearing a long consolidation pattern. Indicators such as relative strength improved, but the stock is now in an extended posture off the breakout. That tends to invite a pullback or sideways digestion while investors reassess risk-reward, particularly given the newly announced formulary action.

What Investors Should Focus On

Key items for investors to monitor over the coming weeks include: (1) Amgen’s efforts to mitigate the CVS formulary shift through contracting or patient-assistance programs; (2) quarterly flows for Prolia and other affected biologics to detect early biosimilar displacement; (3) cadence of organic growth from faster-growing newer products that can offset legacy product erosion; and (4) updates from major analysts that reconcile higher targets with the emerging payer risk.

Conclusion

Amgen’s recent earnings demonstrated the company’s ability to grow revenue and earnings across a diversified product set, which justified the initial stock rally. However, the CVS formulary decision to favor biosimilars for Prolia is a tangible, time-bound commercial risk that can compress revenues for that franchise beginning April 1. For investors, the story is now a trade-off: durable multi-product strength and raised analyst optimism versus an immediate, specific payer-driven headwind. Position sizing and a close watch on prescription flow and contracting developments will be essential for navigating AMGN in the near term.